



Dicerna Pharmaceuticals
Investor Relations Department
87 Cambridgepark Drive
Cambridge, MA 02140
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: DRNA

Last Trade:	7.50
Trade Time:	4:00 PM ET Dec 12, 2017
Change:	-0.20 (-2.597%)
Day Range	7.35 - 7.85
52-Week Range	2.42 - 10.24
Volume	121,846

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Dicerna is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. The Company is using its proprietary GalXC RNAi technology platform to build a broad pipeline in these therapeutic areas.

[Dicerna Corporate Fact Sheet\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Dec 7, 2017*
[Dicerna Announces First Human Dosed in Phase 1 Clinical Trial of DCR-PHXC for Treatment of All Forms of Primary Hyperoxaluria](#)
- Nov 21, 2017*
[Dicerna to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference](#)
- Nov 8, 2017*
[Dicerna to Present at the Stifel 2017 Healthcare Conference](#)
- Nov 2, 2017*
[Dicerna Reports Third Quarter 2017 Financial and Operating Results and Provides Corporate Update](#)
- Nov 2, 2017*
[Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis \(NASH\)](#)

Financials [\[View all \]](#)

- Mar 30, 2017*
[Annual Report \(10-K\)](#)
- May 23, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 2, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 10, 2017*
[Quarterly Report \(10-Q\)](#)
- May 8, 2017*
[Quarterly Report \(10-Q\)](#)